PharmaLytica 2021 Hyderabad review.

Bharat Biotech plans to install four Covaxin manufacturing plants

January 05, 2021

The company is planning to produce 700 million doses per year. Around 200 million doses (per annum) will be produced in Hyderabad, 500 million doses in other cities Bharat Biotech, which has been accorded Emergency Use Authorisation from the drug regulator for its COVID-19 vaccine Covaxin, on Monday said they are setting up four vaccine manufacturing facilities with a combined capacity of 700 million doses per annum.

Denying allegations that the city-based vaccine maker lacks data of Covaxin, Krishna Ella, chairman of Bharat Biotech, said sufficient data has already been revealed and is available on the net.

×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More